Partnerships

PreDicta

The European collaborative project PreDicta was launched in October 2010 in Athens, Greece. The €7.8-million initiative funded in large part by the European Commission set out to answer the question: 'why do asthma symptoms persist?'

Based on the observation that childhood asthma usually occurs after a viral respiratory tract infection, the central hypothesis of the project is that repeated, acute infection-mediated events may reprogram the immune system to predispose towards a chronic inflammation pattern.

The PreDicta consortium integrated 14 partners from 9 European countries, under the coordination of Professor Nikos Papadopoulos from the National and Kapodistrian University of Athens. Leading core units of the consortium have substantially contributed to our current understanding of the role of respiratory infections in asthma, the immuno-inflammatory processes involved and the development of diagnostic and therapeutic approaches for this disease. This academic effort employing the latest technologies of molecular biology, virology and cytology is complemented by the participation of BIOMAY, an Austrian company fully dedicated to the development of novel diagnostic and immunotherapeutic approaches for allergic diseases and asthma.

The final objective of PreDicta was to accurately predict the predisposing risk factors for the development of respiratory allergies and to interfere more effectively with the disease process by targeting causative agents rather than symptoms.

In December 2014, work from PreDicta provided for the first time evidence that increases of antibodies against a portion of the rhinovirus coat protein VP1 might be strain-specific surrogate markers for the severity of rhinovirus-induced respiratory symptoms.
Last updated 17 July 2018
Privacy Policy - disclaimer

EAACI recently updated its privacy policy and would like to highlight some key bits of information with you.

  • EAACI does not distribute, share or sell your information;
  • For technical and administrative purposes some information that can be used to identify you may be forwarded to third parties. For example, to process your registration for the EAACI Annual Congress and other EAACI events;
  • The Academy may also send you e-mail messages with news from the society. If you would like to no longer receive them, you can unsubscribe at any time by using the unsubscribe link in any of our communications;
  • You may also update your preferences or your profile information at any time by contacting us.

To continue please confirm that you agree with our updated privacy policy.

Thank you!

You have successfully agreed the new privacy policy – disclaimer.

Thank you!

You disagreed with the new privacy policy – disclaimer and your feedback will be reviewed as soon as possible.

Agree & Continue
Disagree
Send feedback
Cancel